Literature DB >> 14693617

Postanesthesia care unit recovery times and neuromuscular blocking drugs: a prospective study of orthopedic surgical patients randomized to receive pancuronium or rocuronium.

Glenn S Murphy1, Joseph W Szokol, Mark Franklin, Jesse H Marymont, Michael J Avram, Jeffery S Vender.   

Abstract

UNLABELLED: In this study, we examined the effect of choice of neuromuscular blocking drug (NMBD) (pancuronium versus rocuronium) on postoperative recovery times and associated adverse outcomes in patients undergoing orthopedic surgical procedures. Seventy patients were randomly allocated to a pancuronium or rocuronium group. On arrival to the postanesthesia care unit (PACU) and again 30 min later, train-of-four ratios were quantified by using acceleromyography. Immediately after acceleromyographic measurements, patients were assessed for signs and symptoms of residual paresis. During the PACU admission, episodes of hypoxemia, nausea, and vomiting were recorded. The time required for patients to meet discharge criteria and the time of actual PACU discharge were noted. Forty percent of patients in the pancuronium group had train-of-four ratios <0.7 on arrival to the PACU, compared with only 5.9% of subjects in the rocuronium group (P < 0.001). Patients in the pancuronium group were more likely to experience symptoms of muscle weakness (blurry vision and generalized weakness; P < 0.001) and hypoxemia (10 patients in the rocuronium group versus 21 patients in the pancuronium group; P = 0.015) during the PACU admission. Significant delays in meeting PACU discharge criteria (50 min [45-60 min] versus 30 min [25-40 min]) and achieving actual discharge (70 min [60-90 min] versus 57.5 min [45-61 min]) were observed when the pancuronium group was compared with the rocuronium group (P < 0.001). In conclusion, our study indicates that PACU recovery times may be prolonged when long-acting NMBDs are used in surgical patients. IMPLICATIONS: Clinical recovery may be delayed in surgical patients administered long-acting neuromuscular blocking drugs. During the postanesthesia care unit admission, patients randomized to receive pancuronium (versus rocuronium) were more likely to exhibit symptoms of muscle weakness, develop hypoxemia, and require more time to meet discharge criteria.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14693617     DOI: 10.1213/01.ane.0000095040.36648.f7

Source DB:  PubMed          Journal:  Anesth Analg        ISSN: 0003-2999            Impact factor:   5.108


  16 in total

1.  Neuromuscular Block and Blocking Agents in 2018.

Authors:  Christoph Unterbuchner
Journal:  Turk J Anaesthesiol Reanim       Date:  2018-04-01

Review 2.  Sugammadex compared with neostigmine/glycopyrrolate for routine reversal of neuromuscular block: a systematic review and economic evaluation.

Authors:  F Paton; M Paulden; D Chambers; M Heirs; S Duffy; J M Hunter; M Sculpher; N Woolacott
Journal:  Br J Anaesth       Date:  2010-10-08       Impact factor: 9.166

3.  [Hypoxemia after general anesthesia].

Authors:  H Aust; L H J Eberhart; P Kranke; C Arndt; C Bleimüller; M Zoremba; D Rüsch
Journal:  Anaesthesist       Date:  2012-04       Impact factor: 1.041

4.  Prevention of Postoperative Events following Reversal with Sugammadex or Neostigmine (the P-PERSoN Trial): Pilot Data Following Early Termination of a Prospective, Blinded, Randomised Trial.

Authors:  Benjamin Olesnicky; Matthew Doane; Clare Farrell; Greg Knoblanche; Anthony Delaney
Journal:  Anesthesiol Res Pract       Date:  2022-07-08

Review 5.  [Algorithm-based preventive strategies for avoidance of residual neuromuscular blocks].

Authors:  C Unterbuchner; K Ehehalt; B Graf
Journal:  Anaesthesist       Date:  2019-11       Impact factor: 1.041

6.  A Clinical and Budgetary Impact Analysis of Introducing Sugammadex for Routine Reversal of Neuromuscular Blockade in a Hypothetical Cohort in the US.

Authors:  Yiling Jiang; Lori D Bash; Leif Saager
Journal:  Adv Ther       Date:  2021-04-19       Impact factor: 3.845

Review 7.  Enhanced Recovery After Surgery (ERAS) for gastrointestinal surgery, part 2: consensus statement for anaesthesia practice.

Authors:  A Feldheiser; O Aziz; G Baldini; B P B W Cox; K C H Fearon; L S Feldman; T J Gan; R H Kennedy; O Ljungqvist; D N Lobo; T Miller; F F Radtke; T Ruiz Garces; T Schricker; M J Scott; J K Thacker; L M Ytrebø; F Carli
Journal:  Acta Anaesthesiol Scand       Date:  2015-10-30       Impact factor: 2.105

8.  A discrete event simulation model of clinical and operating room efficiency outcomes of sugammadex versus neostigmine for neuromuscular block reversal in Canada.

Authors:  Ralph P Insinga; Cédric Joyal; Alexandra Goyette; André Galarneau
Journal:  BMC Anesthesiol       Date:  2016-11-16       Impact factor: 2.217

9.  Management of Residual Neuromuscular Blockade Recovery: Age-Old Problem with a New Solution.

Authors:  Michael S Green; Archana Gundigi Venkatesh; Ranjani Venkataramani
Journal:  Case Rep Anesthesiol       Date:  2017-03-14

10.  Introduction of sugammadex as standard reversal agent: Impact on the incidence of residual neuromuscular blockade and postoperative patient outcome.

Authors:  Thomas Ledowski; Samuel Hillyard; Brendan O'Dea; Rob Archer; Filipe Vilas-Boas; Barney Kyle
Journal:  Indian J Anaesth       Date:  2013-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.